Crescent Biopharma is going public through a reverse merger with GlycoMimetics to capitalize on a recent groundbreaking cancer drug development still fresh in investors’ minds. The company’s lead program is a bispecific antibody called CR-001, similar to Summit Therapeutics’ ivonescimab. Crescent aims to replicate the properties of ivonescimab to compete in the checkpoint inhibitor therapy market. The company believes its novel drug design can deliver benefits to patients efficiently and safely. With funding of $200 million from select investors, Crescent plans to advance its drug through preclinical research and expects preliminary clinical data by the second half of 2026.
Source link
Going In Reverse Is Faster Way Forward for Crescent Bio’s Cancer Immunotherapy
